Results 151 to 160 of about 3,855 (201)

Miglustat as Disease-Modifying Therapy in a Patient with SCARB2-Related Action Myoclonus Renal Failure. [PDF]

Mov Disord Clin Pract
Colucci F, Dardis A, Pavan E, Scarpa M, Gozzi A, Antenucci P, Farnè M, Neri M, Ferlini A, Tugnoli V, Sechi A, Sensi M.   +11 more
europepmc   +1 more source

Correction: Miglustat ameliorates isoproterenol-induced cardiac fibrosis via targeting UGCG

Molecular Medicine
Jing Liu, Wenqi Li, Ran Jiao, Zhigang Liu, Tiantian Zhang, Dan Chai, Lingxin Meng, Zhongyi Yang, Yuming Liu, Hongliang Wu, Xiaoting Gu, Xiaohe Li, Cheng Yang   +12 more
doaj   +1 more source

French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher disease. [PDF]

Orphanet J Rare Dis
Camou F, Serratrice C, Pettazzoni M, Nadjar Y, Brassier A, Bekri S, Cador-Rousseau B, Dagneaux L, Dalbies F, Froissart R, Genevaz D, Guemann AS, Hivert B, Leguy-Seguin V, Marcel C, Masseau A, Michaud M, Pers YM, Stirnemann J, Vergnaud S, Nguyen Y, Caillaud C, Pichard S, Berger MG, Belmatoug N.   +24 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Miglustat

Drugs, 2012
exaly   +3 more sources

Dietary modifications in patients receiving miglustat

Journal of Inherited Metabolic Disease, 2010
AbstractWeight loss and gastrointestinal disturbances are often seen during miglustat therapy for lysosomal storage diseases. A retrospective analysis of data from a mixed group of patients treated with miglustat at two UK centres was performed to evaluate the effect of two different dietary interventions on body weight and gastrointestinal ...
Champion, H., Ramaswami, U., Imrie, J., Lachmann, R. H., Gallagher, J., Cox, T. M., Wraith, J. E.   +6 more
openaire   +3 more sources